T-cell and Genome Engineering Lab
The T-cell and Genome Engineering Lab employs high-dimensional profiling of primary human tumor samples from patients undergoing Chimeric Antigen Receptor T-cell (CART) therapy to understand current limitations hereof. Insights gained from single-cell studies then instruct the design of novel synthetic immunoreceptors, which we engineer utilizing our CRISPR/Cas9 knock-in platform. The ultimate goal is to translate our highly efficient and non-viral effector T-cells into clinical trials.
